We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli drugmaker Teva Pharmaceutical Industries has announced that it will cease production at its manufacturing facility in Cidra, Puerto Rico, during the fourth quarter of 2006.
British drugmaker GlaxoSmithKline (GSK) has announced plans to collaborate on a research project on gastrointestinal diseases with the Alimentary Pharmabiotic Centre of the University College Cork, Ireland.
The Drug Controller General of India (DCGI) has granted approval to Venus Remedies, India, for launch of its Fixed Dose Combination (FDC) Drug of latest generation Cephalosporin with an amino-glycoside.
Pfizer Canada announced that it has received Health Canada approval for Revatio (sildenafil citrate), an important new treatment for pulmonary arterial hypertension (PAH), a rare and incurable vascular disease.
The breast cancer drug herceptin will be listed on the Pharmaceutical Benefits Scheme from October 1, saving up to 2000 sufferers a year from having to pay $50,000 for the drug.
Amtech investment house pointed out today a 4% increase in the price of Copaxone, the flagship drug of Israeli pharmaceutical giant Teva Pharmaceutical Industries Ltd. The price hike will apparently boost Tevs's results for the third quarter of this year.
Sanofi-Aventis KK and Astellas Pharma Inc., Japan, have agreed to discontinue the marketing alliance on September 30, 2006 for Ketek Tablets 300 mg (generic name: telithromycin), ketolide antibiotic.
The supervisory board of Croatian drugmaker Pliva said on Wednesday it welcomed a takeover bid by U.S. pharmaceutical firm Barr Pharmaceuticals Inc, arguing it reflected "fair value" for the company.